Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Praxsyn Corporation (PXYN)
Las Vegas, IL, US
Praxsyn Corporation operates as a healthcare enterprise, supplying medical professionals with specific medications and related services for their patients. The company specializes in creating non-narcotic and non-habit-forming treatments, utilizing therapeutic and preventative compounds. These come in various formats, such as transdermal creams, patches, and oral capsules, and are formulated to treat issues like pain management, erectile dysfunction, and metabolic disorders. Praxsyn's offerings are available to patients covered by California's workers' compensation program, along with those under preferred provider contracts. Established in 2005, the company was formerly known as The PAWS Pet Company, Inc. before changing its name to Praxsyn Corporation in March 2014. Its operations are based out of Las Vegas, Nevada.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% | -90.00% | -99.71% | -100.00% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2024-04 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Pharmaceuticals: +7.8%-90.1% Q3'19: -99.8% (vs Q2'15)
-
EPS growth Medical - Pharmaceuticals: +20.2%+83.3% ★ Q3'19: -108.7% (vs Q2'15)
-
FCF margin FCF growth · Medical - Pharmaceuticals: +43.3%-625.0% Q3'19: -14,060.9% (vs Q2'15)
-
EBIT margin Medical - Pharmaceuticals: +6.8%-240.9% Q3'19: -279.1% (vs Q2'15)
-
ROIC Medical - Pharmaceuticals: +6.1%-4.7% Q3'19: -11.4% (vs Q2'15)
-
Share dilution Medical - Pharmaceuticals: +0.0%+1.9% Q3'19: -43.7% (vs Q2'15)
-
Debt / EBITDA Net debt/EBITDA · Medical - Pharmaceuticals: 0.21×-11.84× Q3'19: -4.50× (vs Q2'15)
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Sean Daly | Chief Executive Officer & Director | — | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for PXYN
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
